The numbers tell us one thing and they ultimately suggest a market cap well north of $500M at some point. However, at the end of the day, it's how good of a negotiator Punit and other board members are which will determine what big Pharma will pay?
Here are some possible scenarios:
No partner; go it alone: ~$0.50/share Partnership w/no cash influx: ~$1/share Partnership w/minimal cash influx: $1.25 to $1.75/share. Partnership w/strong cash influx: $2-3/share Multiple partnerships: > $3/share
Lots of variables involved, and I just can't see us staying under $200M market cap much longer.
There are no comparable companies with this small of a pipeline and that high of a market cap. ONCS is only running trials for one type of cancer, and has not done a large study on it. ONCS is in its infancy. The potential is huge, but pps will reflect current results. A market cap this year of 500 million would be overvalued.
News 
Market Data 
Discover 
